PYY3-36: Beyond food intake

Frontiers in Neuroendocrinology

Volumn 38, Issue , 2015, Pages 1-11

  Stadlbauer, Ulrike ^a   Woods, Stephen C ^b   Langhans, Wolfgang ^a   Meyer, Urs ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Dopamine; Eating; Energy homeostasis; Gut peptide; Incentive salience

Indexed keywords

DOPAMINE; PEPTIDE YY; PEPTIDE YY [3-36]; TYROSINE 3 MONOOXYGENASE;

ANIMAL; CONCEPTUAL FRAMEWORK; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; EATING; FOOD INTAKE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GASTROINTESTINAL ABSORPTION; HOMEOSTASIS; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; IMMUNOHISTOCHEMISTRY; LONG TERM MEMORY; MESOLIMBIC DOPAMINERGIC SYSTEM; METABOLISM; NEUROMODULATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; WORKING MEMORY;

ANIMALS; DOPAMINE; EATING; GASTROINTESTINAL ABSORPTION; HOMEOSTASIS; HUMANS; METABOLISM; PEPTIDE YY; PHYSIOLOGY;

EID: 84931562831     PISSN: 00913022     EISSN: 10956808     Source Type: Journal    
DOI: 10.1016/j.yfrne.2014.12.003     Document Type: Review

References (158)

1. Abbott C.R., Small C.J., Kennedy A.R., Neary N.M., Sajedi A., Ghatei M.A., Bloom S.R. Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Brain Res. 2005, 1043(1-2):139-144.
2. Acuna-Goycolea C., van den Pol A.N. Peptide YY(3-36) inhibits both anorexigenic proopiomelanocortin and orexigenic neuropeptide Y neurons: implications for hypothalamic regulation of energy homeostasis. J. Neurosci. 2005, 25(45):10510-10519.
3. Adewale A.S., Macarthur H., Westfall T.C. Neuropeptide Y induced modulation of dopamine synthesis in the striatum. Regul. Pept. 2005, 129(1-3):73-78.
4. Adewale A.S., Macarthur H., Westfall T.C. Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors. Neuropharmacology 2007, 52(6):1396-1402.
5. Adrian T.E., Ferri G.L., Bacarese-Hamilton A.J., Fuessl H.S., Polak J.M., Bloom S.R. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985, 89(5):1070-1077.
6. Alvarez Bartolomé M., Borque M., Martinez-Sarmiento J., Aparicio E., Hernández C., Cabrerizo L., Fernández-Represa J.A. Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes. Surg. 2002, 12(3):324-327.
7. Arnt J., Bogeso K.P., Hyttel J., Meier E. Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats. Pharmacol. Toxicol. 1988, 62(3):121-130.
8. Baddeley A. Working memory: looking back and looking forward. Nat. Rev. Neurosci. 2003, 4(10):829-839.
9. Baldock P.A., Sainsbury A., Couzens M., Enriquez R.F., Thomas G.P., Gardiner E.M., Herzog H. Hypothalamic Y2 receptors regulate bone formation. J. Clin. Invest. 2002, 109(7):915-921.
10. Bardo M.T., Donohew R.L., Harrington N.G. Psychobiology of novelty seeking and drug seeking behavior. Behav. Brain Res. 1996, 77(1-2):23-43.
11. Batterham R.L., Cowley M.A., Small C.J., Herzog H., Cohen M.A., Dakin C.L., Wren A.M., Brynes A.E., Low M.J., Ghatei M.A., Cone R.D., Bloom S.R. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002, 418(6898):650-654.
12. Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Withers D.J., Frost G.S., Ghatei M.A., Bloom S.R. Inhibition of food intake in obese subjects by peptide YY3-36. N. Engl. J. Med. 2003, 349(10):941-948.
13. Batterham R.L., Heffron H., Kapoor S., Chivers J.E., Chandarana K., Herzog H., Le Roux C.W., Thomas E.L., Bell J.D., Withers D.J. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab. 2006, 4(3):223-233.
14. Batterham R.L., ffytche D.H., Rosenthal J.M., Zelaya F.O., Barker G.J., Withers D.J., Williams S.C. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 2007, 450(7166):106-109.
15. Beckmann J.S., Marusich J.A., Gipson C.D., Bardo M.T. Novelty seeking, incentive salience and acquisition of cocaine self-administration in the rat. Behav. Brain Res. 2011, 216(1):159-165.
16. Begg D.P., Woods S.C. The endocrinology of food intake. Nat. Rev. Endocrinol. 2013, 9(10):584-597.
17. Berglund M.M., Hipskind P.A., Gehlert D.R. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp. Biol. Med. (Maywood) 2003, 228(3):217-244.
18. Berridge K.C. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology 2007, 191(3):391-431.
19. Berridge K.C., Robinson T.E. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?. Brain Res. Brain Res. Rev. 1998, 28(3):309-369.
20. Berridge K.C., Robinson T.E., Aldridge J.W. Dissecting components of reward: 'liking', 'wanting', and learning. Curr. Opin. Pharmacol. 2009, 9(1):65-73.
21. Berthoud H.R. Metabolic and hedonic drives in the neural control of appetite: who is the boss?. Curr. Opin. Neurobiol. 2011, 21(6):888-896.
22. Berthoud H.R., Lenard N.R., Shin A.C. Food reward, hyperphagia, and obesity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 300(6):R1266-R1277.
23. Bitanihirwe B.K., Peleg-Raibstein D., Mouttet F., Feldon J., Meyer U. Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia. Neuropsychopharmacology 2010, 35(12):2462-2478.
24. Björklund A., Dunnett S.B. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007, 30(5):194-202.
25. Blanchard M.M., Mendelsohn D., Stamp J.A. The HR/LR model: Further evidence as an animal model of sensation seeking. Neurosci. Biobehav. Rev. 2009, 33(7):1145-1154.
26. Blum K., Braverman E.R., Holder J.M., Lubar J.F., Monastra V.J., Miller D., Lubar J.O., Chen T.J., Comings D.E. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J. Psychoactive Drugs 2000, 32(Suppl. i-iv):1-112.
27. Boey D., Lin S., Karl T., Baldock P., Lee N., Enriquez R., Couzens M., Slack K., Dallmann R., Sainsbury A., Herzog H. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 2006, 49:1360-1370.
28. Boey D., Lin S., Enriquez R.F., Lee N.J., Slack K., Couzens M., Baldock P.A., Herzog H., Sainsbury A. PYY transgenic mice are protected against diet-induced and genetic obesity. Neuropeptides 2008, 42(1):19-30.
29. Borbély E., Scheich B., Helyes Z. Neuropeptides in learning and memory. Neuropeptides 2013, 47(6):439-450.
30. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 2001, 156(2-3):234-258.
31. Broberger C., Landry M., Wong H., Walsh J.N., Hokfelt T. Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology 1997, 66(6):393-408.
32. Cabib S., Puglisi-Allegra S. Different effects of apomorphine on climbing behavior and locomotor activity in three strains of mice. Pharmacol. Biochem. Behav. 1985, 23(4):555-557.
33. Cabrele C., Beck-Sickinger A.G. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family. J. Pept. Sci. 2000, 6(3):97-122.
34. Cannon C.M., Abdallah L., Tecott L.H., During M.J., Palmiter R.D. Dysregulation of striatal dopamine signaling by amphetamine inhibits feeding by hungry mice. Neuron 2004, 44(3):509-520.
35. Carlini V.P., Martini A.C., Schiöth H.B., Ruiz R.D., Fiol de Cuneo M., de Barioglio S.R. Decreased memory for novel object recognition in chronically food-restricted mice is reversed by acute ghrelin administration. Neuroscience 2008, 153(4):929-934.
36. Challis B.G., Pinnock S.B., Coll A.P., Carter R.N., Dickson S.L., O'Rahilly S. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem. Biophys. Res. Commun. 2003, 311(4):915-919.
37. Chandarana K., Batterham R. Peptide YY. Curr. Opin. Endocrinol. Diabetes Obes. 2008, 15(1):65-72.
38. Chandarana K., Gelegen C., Karra E., Choudhury A.I., Drew M.E., Fauveau V., Viollet B., Andreelli F., Withers D.J., Batterham R.L. Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY. Diabetes 2011, 60:810-818.
39. Charntikov S., Der-Ghazarian T., Herbert M.S., Horn L.R., Widarma C.B., Gutierrez A., Varela F.A., McDougall S.A. Importance of D1 and D2 receptors in the dorsal caudate-putamen for the locomotor activity and stereotyped behaviors of preweanling rats. Neuroscience 2011, 183:121-133.
40. Chelikani P.K., Haver A.C., Reidelberger R.D. Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology 2005, 146(2):879-888.
41. Chelikani P.K., Haver A.C., Reidelberger R.D. Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293(1):R39-R46.
42. Cox J.E., Randich A. Enhancement of feeding suppression by PYY(3-36) in rats with area postrema ablations. Peptides 2004, 25(6):985-989.
43. Creese I., Iversen S.D. The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Res. 1975, 83(3):419-436.
44. David H.N., Ansseau M., Abraini J.H. Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate-putamen and nucleus accumbens of "intact" animals. Brain Res. Brain Res. Rev. 2005, 50(2):336-360.
45. De Silva A., Salem V., Long C.J., Makwana A., Newbould R.D., Rabiner E.A., Ghatei M.A., Bloom S.R., Matthews P.M., Beaver J.D., Dhillo W.S. The gut hormones PYY3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab. 2011, 14:700-706.
46. Degen L., Oesch S., Casanova M., Graf S., Ketterer S., Drewe J., Beglinger C. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005, 129(5):1430-1436.
47. dos Santos V.V., Santos D.B., Lach G., Rodrigues A.L., Farina M., De Lima T.C., Prediger R.D. Neuropeptide Y (NPY) prevents depressive-like behavior, spatial memory deficits and oxidative stress following amyloid-β (Aβ(1-40)) administration in mice. Behav. Brain Res. 2013, 244:107-115.
48. Fukushiro D.F., Frussa-Filho R. Chronic amphetamine transforms the emotional significance of a novel but not a familiar environment: implications for addiction. Int. J. Neuropsychopharmacol. 2011, 14(7):955-965.
49. Gehlert D.R. Subtypes of receptors for neuropeptide Y: implications for the targeting of therapeutics. Life Sci. 1994, 55:551-562.
50. Glimcher P.W. Understanding dopamine and reinforcement learning: the dopamine reward prediction error hypothesis. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(Suppl. 3):15647-15654.
51. Gonçalves J., Baptista S., Olesen M.V., Fontes-Ribeiro C., Malva J.O., Woldbye D.P., Silva A.P. Methamphetamine-induced changes in the mice hippocampal neuropeptide Y system: implications for memory impairment. J. Neurochem. 2012, 123(6):1041-1053.
52. Graham F.K. The more or less startling effects of weak prestimulation. Psychophysiology 1975, 12:238-248.
53. Grandt D., Schimiczek M., Beglinger C., Layer P., Goebell H., Eysselein V.E., et al. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul. Pept. 1994, 51(2):151-159.
54. Groenewegen H.J. The basal ganglia and motor control. Neural Plast. 2003, 10(1-2):107-120.
55. Groenewegen H.J., Wright C.I., Beijer A. The nucleus accumbens: gateway for limbic structures to reach the motor system?. Prog. Brain Res. 1996, 107:485-511.
56. Guo Y., Ma L., Enriori P.J., Koska J., Franks P.W., Brookshire T., Cowley M.A., Salbe A.D., Delparigi A., Tataranni P.A. Physiological evidence for the involvement of peptide YY in the regulation of energy homeostasis in humans. Obesity (Silver Spring) 2006, 14(9):1562-1570.
57. Hahn T.M., Breininger J.F., Baskin D.G., Schwartz M.W. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat. Neurosci. 1998, 1(4):271-272.
58. Halatchev I.G., Cone R.D. Peripheral administration of PYY(3-36) produces conditioned taste aversion in mice. Cell Metab. 2005, 1(3):159-168.
59. Hartshorne J.K. Visual working memory capacity and proactive interference. PLoS ONE 2008, 3(7):e2716.
60. Heffner T.G., Zigmond M.J., Stricker E.M. Effects of dopaminergic agonists and antagonists of feeding in intact and 6-hydroxydopamine-treated rats. J. Pharmacol. Exp. Ther. 1977, 201(2):386-399.
61. Heidbreder C., Feldon J. Amphetamine-induced neurochemical and locomotor responses are expressed differentially across the anteroposterior axis of the core and shell subterritories of the nucleus accumbens. Synapse 1998, 29(4):310-322.
62. Hnasko T.S., Szczypka M.S., Alaynick W.A., During M.J., Palmiter R.D. A role for dopamine in feeding responses produced by orexigenic agents. Brain Res. 2004, 1023(2):309-318.
63. Hoffman H.S., Searle J.L. Acoustic variables in the modification of startle reaction in the rat. J. Comp. Physiol. Psychol. 1965, 60:53-58.
64. Imamura M. Effects of surgical manipulation of the intestine on peptide YY and its physiology. Peptides 2002, 23:403-407.
65. Inoue K., Zorrilla E.P., Tabarin A., Valdez G.R., Iwasaki S., Kiriike N., Koob G.F. Reduction of anxiety after restricted feeding in the rat: implication for eating disorders. Biol. Psychiatry 2004, 55(11):1075-1081.
66. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 2003, 160(1):13-23.
67. Karl T., Chesworth R., Duffy L., Herzog H. Schizophrenia-relevant behaviours in a genetic mouse model for Y2 deficiency. Behav. Brain Res. 2010, 207(2):434-440.
68. Karra E., Batterham R.L. The role of gut hormones in the regulation of body weight and energy homeostasis. Mol. Cell. Endocrinol. 2010, 316(2):120-128.
69. Karra E., Chandarana K., Batterham R.L. The role of peptide YY in appetite regulation and obesity. J. Physiol. 2009, 15(587):19-25.
70. Kenny P.J. Common cellular and molecular mechanisms in obesity and drug addiction. Nat. Rev. Neurosci. 2011, 12(11):638-651.
71. Khabour O.F., Alzoubi K.H., Alomari M.A., Alzubi M.A. Changes in spatial memory and BDNF expression to concurrent dietary restriction and voluntary exercise. Hippocampus 2010, 20(5):637-645.
72. King P.J., Widdowson P.S., Doods H.N., Williams G. Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices. J. Neurochem. 1999, 73(2):641-646.
73. Kirchner H., Tong J., Tschöp M.H., Pfluger P.T. Ghrelin and PYY in the regulation of energy balance and metabolism: lessons from mouse mutants. Am. J. Physiol. Endocrinol. Metab. 2010, 298:909-919.
74. Kodsi M.H., Swerdlow N.R. Prepulse inhibition in the rat is regulated by ventral and caudodorsal striato-pallidal circuitry. Behav. Neurosci. 1995, 109(5):912-928.
75. Koegler F.H., Enriori P.J., Billes S.K., Takahashi D.L., Martin M.S., Clark R.L., Evans A.E., Grove K.L., Cameron J.L., Cowley M.A. Peptide YY(3-36) inhibits morning, but not evening, food intake and decreases body weight in rhesus macaques. Diabetes 2005, 54(11):3198-3204.
76. B receptors in cortical network activity. Adv. Pharmacol. 2010, 58:205-229.
77. Kretschmer B.D., Koch M. The ventral pallidum mediates disruption of prepulse inhibition of the acoustic startle response induced by dopamine agonists, but not by NMDA antagonists. Brain Res. 1998, 798(1-2):204-210.
78. Labouesse M.A., Stadlbauer U., Langhans W., Meyer U. Chronic high fat diet consumption impairs sensorimotor gating in mice. Psychoneuroendocrinology 2013, 38(11):2562-2574.
79. Laricchiuta D., Musella A., Rossi S., Centonze D. Behavioral and electrophysiological effects of endocannabinoid and dopaminergic systems on salient stimuli. Front. Behav. Neurosci. 2014, 19(8):183.
80. le Roux C.W., Batterham R.L., Aylwin S.J., Patterson M., Borg C.M., Wynne K.J., Kent A., Vincent R.P., Gardiner J., Ghatei M.A., Bloom S.R. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006, 147(1):3-8.
81. le Roux C.W., Borg C.M., Murphy K.G., Vincent R.P., Ghatei M.A., Bloom S.R. Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake. Ann. Clin. Biochem. 2008, 45(Pt 1):93-95.
82. Lewis D.A., Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch. Neurol. 2006, 63(10):1372-1376.
83. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 2005, 6(4):312-324.
84. Lubow R.E. Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia. Schizophr. Bull. 2005, 31(1):139-153.
85. Lubow R.E., Moore A.U. Latent inhibition: the effect of nonreinforced pre-exposure to the conditional stimulus. J. Comp. Physiol. Psychol. 1959, 52:415-419.
86. Lubow R.E., Weiner I., Schnur P. Conditioned attention theory. The Psychology of Learning and Motivation 1981, Academic, New York. G.H. Bower (Ed.).
87. Mackintosh N.J. A theory of attention: variations in the associability of stimuli with reinforcement. Psychol. Rev. 1975, 82:276-298.
88. Manning S., Batterham R.L. The role of gut hormone peptide YY in energy and glucose homeostasis: twelve years on. Annu. Rev. Physiol. 2014, 76:585-608.
89. Marinelli M., White F.J. Enhanced vulnerability to cocaine self-administration is associated with elevated impulse activity of midbrain dopamine neurons. J. Neurosci. 2000, 20(23):8876-8885.
90. Martin N.M., Small C.J., Sajedi A., Patterson M., Ghatei M.A., Bloom S.R. Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY(3-36) but resistant to ghrelin. Int. J. Obes. Relat. Metab. Disord. 2004, 28(7):886-893.
91. Matthews M., Bondi C., Torres G., Moghaddam B. Reduced presynaptic dopamine activity in adolescent dorsal striatum. Neuropsychopharmacology 2013, 38(7):1344-1351.
92. McLaughlin I.B., Dess N.K., Chapman C.D. Modulation of methylphenidate effects on wheel running and acoustic startle by acute food deprivation in commercially and selectively bred rats. Pharmacol. Biochem. Behav. 2011, 97(3):500-508.
93. Medeiros M.D., Turner A.J. Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24. II. Endocrinology 1994, 134(5):2088-2094.
94. Mele A., Thomas D.N., Pert A. Different neural mechanisms underlie dizocilpine maleate- and dopamine agonist-induced locomotor activity. Neuroscience 1998, 82(1):43-58.
95. Mentlein R., Dahms P., Grandt D., Kruger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul. Pept. 1993, 49:133-144.
96. Meyer U., Feldon J. Neural basis of psychosis-related behaviour in the infection model of schizophrenia. Behav. Brain Res. 2009, 204(2):322-334.
97. Meyer U., Feldon J. Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog. Neurobiol. 2010, 90(3):285-326.
98. Michel M.C., Beck-Sickinger A., Cox H., Doods H.N., Herzog H., Larhammar D., Quirion R., Schwartz T., Westfall T. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 1998, 50(1):143-150.
99. Morales-Medina J.C., Dumont Y., Bonaventure P., Quirion R. Chronic administration of the Y2 receptor antagonist, JNJ-31020028, induced anti-depressant like-behaviors in olfactory bulbectomized rat. Neuropeptides 2012, 46(6):329-334.
100. Moran T.H., Smedh U., Kinzig K.P., Scott K.A., Knipp S., Ladenheim E.E. Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288(2):384-388.
101. Morton G.J., Meek T.H., Schwartz M.W. Neurobiology of food intake in health and disease. Nat. Rev. Neurosci. 2014, 15(6):367-378.
102. Moy S.S., Nadler J.J., Young N.B., Nonneman R.J., Segall S.K., Andrade G.M., Crawley J.N., Magnuson T.R. Social approach and repetitive behavior in eleven inbred mouse strains. Behav. Brain Res. 2008, 191(1):118-129.
103. Neary M.T., Batterham R.L. Peptide YY: food for thought. Physiol. Behav. 2013, 97(5):616-619.
104. Nelson A.J., Thur K.E., Marsden C.A., Cassaday H.J. Dopamine in nucleus accumbens: salience modulation in latent inhibition and overshadowing. J. Psychopharmacol. 2011, 25(12):1649-1660.
105. Nonaka N., Shioda S., Niehoff M.L., Banks W.A. Characterization of blood-brain barrier permeability to PYY3-36 in the mouse. J. Pharmacol. Exp. Ther. 2003, 306(3):948-953.
106. Nordheim U., Hofbauer K.G. Stimulation of NPY Y2 receptors by PYY3-36 reveals divergent cardiovascular effects of endogenous NPY in rats on different dietary regimens. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 286(1):138-142.
107. Peleg-Raibstein D., Feldon J., Meyer U. Behavioral animal models of antipsychotic drug actions. Handb. Exp. Pharmacol. 2012, 212:361-406.
108. Peters J.R., Vallie B., Difronzo M., Donaldson S.T. Role of dopamine D1 receptors in novelty seeking in adult female Long-Evans rats. Brain Res. Bull. 2007, 74(4):232-236.
109. Pijnenburg A.J., Honig W.M., Van der Heyden J.A., Van Rossum J.M. Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity. Eur. J. Pharmacol. 1976, 35(1):45-58.
110. Pittner R.A., Moore C.X., Bhavsar S.P., Gedulin B.R., Smith P.A., Jodka C.M., Parkes D.G., Paterniti J.R., Srivastava V.P., Young A.A. Effects of PYY[3-36] in rodent models of diabetes and obesity. Int. J. Obes. Relat. Metab. Disord. 2004, 28(8):963-971.
111. Pothos E.N., Sulzer D., Hoebel B.G. Plasticity of quantal size in ventral midbrain dopamine neurons: possible implications for the neurochemistry of feeding and reward. Appetite 1998, 31(3):405.
112. Rajab E., Alqanbar B., Naiser M.J., Abdulla H.A., Al-Momen M.M., Kamal A. Sex differences in learning and memory following short-term dietary restriction in the rat. Int. J. Dev. Neurosci. 2014, 36:74-80.
113. Rebec G.V., Christensen J.R., Guerra C., Bardo M.T. Regional and temporal differences in real-time dopamine efflux in the nucleus accumbens during free-choice novelty. Brain Res. 1997, 776(1-2):61-67.
114. Redrobe J.P., Dumont Y., Herzog H., Quirion R. Characterization of neuropeptide Y, Y(2) receptor knockout mice in two animal models of learning and memory processing. J. Mol. Neurosci. 2004, 22(3):159-166.
115. Richard J.M., Castro D.C., Difeliceantonio A.G., Robinson M.J., Berridge K.C. Mapping brain circuits of reward and motivation: in the footsteps of Ann Kelley. Neurosci. Biobehav. Rev. 2013, 37(9):1919-1931.
116. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. 1986, 396(2):157-198.
117. Roeper J. Dissecting the diversity of midbrain dopamine neurons. Trends Neurosci. 2013, 36(6):336-342.
118. Rüttimann E.B., Arnold M., Hillebrand J.J., Geary N., Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009, 150(3):1174-1181.
119. Salahpour A., Ramsey A.J., Medvedev I.O., Kile B., Sotnikova T.D., Holmstrand E., et al. Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(11):4405-4410.
120. Salamone J.D., Correa M. The mysterious motivational functions of mesolimbic dopamine. Neuron 2012, 76(3):470-485.
121. Sanderson D.J., Bannerman D.M. The role of habituation in hippocampus-dependent spatial working memory tasks: evidence from GluA1 AMPA receptor subunit knockout mice. Hippocampus 2012, 22(5):981-994.
122. Sanderson D.J., Good M.A., Skelton K., Sprengel R., Seeburg P.H., Rawlins J.N., Bannerman D.M. Enhanced long-term and impaired short-term spatial memory in GluA1 AMPA receptor subunit knockout mice: evidence for a dual-process memory model. Learn. Mem. 2009, 16(6):379-386.
123. Schwartz T.W., Holst B. An enteroendocrine full package solution. Cell Metab. 2010, 11(6):445-447.
124. Schwartz M.W., Woods S.C., Porte D., Seeley R.J., Baskin D.G. Central nervous system control of food intake. Nature 2000, 404(6778):661-671.
125. Singer P., Hauser J., Llano Lopez L., Peleg-Raibstein D., Feldon J., Gargiulo P.A., Yee B.K. Prepulse inhibition predicts working memory performance whilst startle habituation predicts spatial reference memory retention in C57BL/6 mice. Behav. Brain Res. 2013, 242:166-177.
126. Sloth B., Davidsen L., Holst J.J., Flint A., Astrup A. Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Am. J. Physiol. Endocrinol. Metab. 2007, 293(2):E604-E609.
127. Smith Y., Kieval J.Z. Anatomy of the dopamine system in the basal ganglia. Trends Neurosci. 2000, 23(10):S28-S33.
128. Smith A., Li M., Becker S., Kapur S. Dopamine, prediction error and associative learning: a model-based account. Network 2006, 17(1):61-84.
129. Smith-White M.A., Hardy T.A., Brock J.A., Potter E.K. Effects of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at peripheral neuroeffector junctions. Br. J. Pharmacol. 2001, 132(4):861-868.
130. Soderpalm B., Ericson M. Neurocircuitry involved in the development of alcohol addiction: the dopamine system and its access points. Curr. Top. Behav. Neurosci. 2013, 13:127-161.
131. Sodowski K., Zwirska-Korczala K., Kuka D., Kukla M., Budziszewska P., Czuba B., Włoch A., Cnota W., Bielański W., Brzozowski T., Rehfeld J.F., Zdun R., Konturek P.C. Basal and postprandial gut peptides affecting food intake in lean and obese pregnant women. J. Physiol. Pharmacol. 2007, 58(Suppl. 1):37-52.
132. Stadlbauer U., Arnold M., Weber E., Langhans W. Possible mechanisms of circulating PYY-induced satiation in male rats. Endocrinology 2013, 154(1):193-204.
133. Stadlbauer U., Langhans W., Meyer U. Administration of the Y2 receptor agonist PYY3-36 in mice induces multiple behavioral changes relevant to schizophrenia. Neuropsychopharmacology 2013, 38(12):2446-2455.
134. Stadlbauer U., Weber E., Langhans W., Meyer U. The Y2 receptor agonist PYY(3-36) increases the behavioural response to novelty and acute dopaminergic drug challenge in mice. Int. J. Neuropsychopharmacol. 2014, 17(3):407-419.
135. Stanic D., Brumovsky P., Fetissov S., Shuster S., Herzog H., Hokfelt T. Characterization of neuropeptide Y2 receptor protein expression in the mouse brain. I. Distribution in cell bodies and nerve terminals. J. Comp. Neurol. 2006, 499(3):357-390.
136. Stanic D., Mulder J., Watanabe M., Hokfelt T. Characterization of NPY Y2 receptor protein expression in the mouse brain. II. Coexistence with NPY, the Y1 receptor, and other neurotransmitter-related molecules. J. Comp. Neurol. 2011, 519(7):1219-1257.
137. Stanley S., Wynne K., Bloom S. Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286(5):G693-G697.
138. Swerdlow N.R., Koob G.F. Lesions of the dorsomedial nucleus of the thalamus, medial prefrontal cortex and pedunculopontine nucleus: effects on locomotor activity mediated by nucleus accumbens-ventral pallidal circuitry. Brain Res. 1987, 412(2):233-243.
139. Swerdlow N.R., Braff D.L., Geyer M.A. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav. Pharmacol. 2000, 11(3-4):185-204.
140. Swerdlow N.R., Geyer M.A., Braff D.L. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 2001, 156(2-3):194-215.
141. Tindell A.J., Berridge K.C., Zhang J., Peciña S., Aldridge J.W. Ventral pallidal neurons code incentive motivation: amplification by mesolimbic sensitization and amphetamine. Eur. J. Neurosci. 2005, 22(10):2617-2634.
142. Tzschentke T.M. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog. Neurobiol. 2001, 63(3):241-320.
143. Van den Heuvel D.M., Pasterkamp R.J. Getting connected in the dopamine system. Prog. Neurobiol. 2008, 85(1):75-93.
144. Vasse M., Protais P. Potentiation of apomorphine-induced stereotyped behaviour by acute treatment with dopamine depleting agents: a potential role for an increased stimulation of D1 dopamine receptors. Neuropharmacology 1989, 28(9):931-939.
145. Volkow N.D., Wise R.A. How can drug addiction help us understand obesity?. Nat. Neurosci. 2005, 8(5):555-560.
146. Volkow N.D., Wang G.J., Fowler J.S., Telang F. Overlapping neuronal circuits in addiction and obesity: evidence of systems pathology. Philos. Trans. Roy. Soc. Lond. B Biol. Sci. 2008, 363(1507):3191-3200.
147. Vuillermot S., Joodmardi E., Perlmann T., Ove Ogren S., Feldon J., Meyer U. Schizophrenia-relevant behaviors in a genetic mouse model of constitutive Nurr1 deficiency. Genes Brain Behav. 2011, 10(5):589-603.
148. Walther C., Mörl K., Beck-Sickinger A.G. Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development. J. Pept. Sci. 2011, 17(4):233-246.
149. Weiner I. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology 2003, 169:257-297.
150. 15O PET study. Neuroimage 2012, 60:592-600.
151. Widdowson P.S. Quantitative receptor autoradiography demonstrates a differential distribution of neuropeptide-Y Y1 and Y2 receptor subtypes in human and rat brain. Brain Res. 1993, 631:27-38.
152. Winton-Brown T.T., Fusar-Poli P., Ungless M.A., Howes O.D. Dopaminergic basis of salience dysregulation in psychosis. Trends Neurosci. 2014, 37(2):85-94.
153. Wise R.A. Dopamine, learning and motivation. Nat. Rev. Neurosci. 2004, 5(6):483-494.
154. Woods S.C., Langhans W. Inconsistencies in the assessment of food intake. Am. J. Physiol. Endocrinol. Metab. 2012, 303(12):E1408-E1418.
155. Woods S.C., Ramsay D.S. Food intake, metabolism and homeostasis. Physiol. Behav. 2011, 104(1):4-7.
156. Yang H. Central and peripheral regulation of gastric acid secretion by peptide YY. Peptides 2002, 23:349-358.
157. Young A.M., Moran P.M., Joseph M.H. The role of dopamine in conditioning and latent inhibition: what, when, where and how?. Neurosci. Biobehav. Rev. 2005, 29(6):963-976.
158. Zambello E., Zanetti L., Hédou G.F., Angelici O., Arban R., Tasan R.O., Sperk G., Caberlotto L. Neuropeptide Y-Y2 receptor knockout mice: influence of genetic background on anxiety-related behaviors. Neuroscience 2011, 10(176):420-430.